191 related articles for article (PubMed ID: 25001264)
1. Biomarker validation: common data analysis concerns.
Ensor JE
Oncologist; 2014 Aug; 19(8):886-91. PubMed ID: 25001264
[TBL] [Abstract][Full Text] [Related]
2. Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.
Dobbin KK; Cesano A; Alvarez J; Hawtin R; Janetzki S; Kirsch I; Masucci GV; Robbins PB; Selvan SR; Streicher HZ; Zhang J; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():77. PubMed ID: 27891226
[TBL] [Abstract][Full Text] [Related]
3. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
4. Pragmatic issues in biomarker evaluation for targeted therapies in cancer.
de Gramont A; Watson S; Ellis LM; Rodón J; Tabernero J; de Gramont A; Hamilton SR
Nat Rev Clin Oncol; 2015 Apr; 12(4):197-212. PubMed ID: 25421275
[TBL] [Abstract][Full Text] [Related]
5. Strategies for power calculations in predictive biomarker studies in survival data.
Chen DT; Huang PY; Lin HY; Haura EB; Antonia SJ; Cress WD; Gray JE
Oncotarget; 2016 Dec; 7(49):80373-80381. PubMed ID: 27661007
[TBL] [Abstract][Full Text] [Related]
6. Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers.
Sargent DJ; Mandrekar SJ
Clin Trials; 2013 Oct; 10(5):647-52. PubMed ID: 23983158
[TBL] [Abstract][Full Text] [Related]
7. How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review.
Seo MK; Cairns J
BMC Cancer; 2021 Sep; 21(1):980. PubMed ID: 34470603
[TBL] [Abstract][Full Text] [Related]
8. Using Somatic Mutations to Guide Treatment Decisions: Context Matters.
Horlings HM; Shah SP; Huntsman DG
JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166
[No Abstract] [Full Text] [Related]
9. Quantitative assessment of a prognostic or predictive biomarker panel.
Korn EL; Freidlin B
J Biopharm Stat; 2018; 28(2):264-281. PubMed ID: 29083961
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic epigenetic biomarkers in cancer.
Costa-Pinheiro P; Montezuma D; Henrique R; Jerónimo C
Epigenomics; 2015; 7(6):1003-15. PubMed ID: 26479312
[TBL] [Abstract][Full Text] [Related]
11. The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.
Jiang X; Pissaloux D; De La Fouchardiere C; Desseigne F; Wang Q; Attignon V; Fondrevelle ME; De La Fouchardiere A; Perol M; Cassier P; Seigne C; Perol D; Ray-Coquard I; Meeus P; Fayette J; Flechon A; Le Cesne A; Penel N; Tredan O; Blay JY
Oncotarget; 2015 Sep; 6(28):26388-99. PubMed ID: 26317543
[TBL] [Abstract][Full Text] [Related]
12. Phase II cancer clinical trials for biomarker-guided treatments.
Jung SH
J Biopharm Stat; 2018; 28(2):256-263. PubMed ID: 28902567
[TBL] [Abstract][Full Text] [Related]
13. Identification and Complete Validation of Prognostic Gene Signatures for Human Papillomavirus-Associated Cancers: Integrated Approach Covering Different Anatomical Locations.
Kwon EJ; Ha M; Jang JY; Kim YH
J Virol; 2021 Feb; 95(6):. PubMed ID: 33361419
[TBL] [Abstract][Full Text] [Related]
14. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
15. Biomarker-Driven Treatments Yield Better Results.
Cancer Discov; 2016 Aug; 6(8):OF4. PubMed ID: 27357459
[TBL] [Abstract][Full Text] [Related]
16. Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial.
Khoury JD; Wang WL; Prieto VG; Medeiros LJ; Kalhor N; Hameed M; Broaddus R; Hamilton SR
Clin Cancer Res; 2018 Feb; 24(3):521-531. PubMed ID: 28839110
[TBL] [Abstract][Full Text] [Related]
17. Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy.
Hou Q; Xu H
Adv Exp Med Biol; 2020; 1248():143-166. PubMed ID: 32185710
[TBL] [Abstract][Full Text] [Related]
18. TP53 is not a prognostic marker-clinical consequences of a generally disregarded fact.
Braunschmid T; Kührer I; Mittlböck M; Westerhoff M; Kappel-Latif S; Brammen L; Krishnadath KK; Phillips WA; Gnant M; Kandioler D
Ann N Y Acad Sci; 2018 Dec; 1434(1):46-53. PubMed ID: 30112858
[TBL] [Abstract][Full Text] [Related]
19. Selected Articles from This Issue.
Clin Cancer Res; 2020 May; 26(10):2279. PubMed ID: 32414759
[No Abstract] [Full Text] [Related]
20. Status of Immune Oncology: Challenges and Opportunities.
Cesano A; Marincola FM; Thurin M
Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
